Skip to main content
Premium Trial:

Request an Annual Quote

Innogenetics' First-Half '08 Revenues Rise 12 Percent

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Innogenetics today reported that its first-half 2008 revenues rose 12 percent, but its net loss inched up 2.6 percent on restructuring and impairment charges.
 
The Gent, Belgium-based company brought in revenues of €30.6 million ($45.1 million) for the six-month period ended June 30, compared with revenues of €27.4 million in the first half of 2007. Innogenetics said that its diagnostic product sales rose 8.4 percent year over year to €25.8 million, driven by sales of infectious diseases and Alzheimer’s disease diagnostics.
 
The firm’s first-half net loss was €8 million, or €.26 per share, compared to a net loss of €7.8 million, or €.25 per share, for the comparable period a year ago.
 
The 2008 first-half results include €8 million in non-recurring restructuring and impairment charges related to the termination of the firm’s GENimmune therapeutic activities. It also includes a $9.5 million settlement with Abbott Laboratories, under which Abbott licensed rights to Innogenetics’ hepatitis C genotyping patents. Innogenetics said that it received all cash from the settlement during the first half of this year.
 
The firm finished the first half with €15.7 million in cash.
 
Innogenetics is in the process of being acquired by Solvay Pharmaceuticals for roughly $316 million. Gen-Probe had also bid to acquire Innogenetics but pulled out after Solvay raised its offering price for the firm.
 
 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more